Meetings with regulatory authorities confirm Ph 3 design
Today IRLAB announced progress with the mesdopetam Ph 3 programme. While the company did not find a mesdopetam partner yet, they continue talks to regulatory authorities in Germany (GER) and Portugal (PT), to align on the design of the planned Ph 3 programme. The country-level regulatory authorities agreed with the FDA-proposed mesdopetam Ph 3 design, as outlined previously. The next step for IRLAB will be interactions with the EMA.
Aktuellt
SENASTE
